Hantao Shu

This paper introduces scPRS, a deep learning model that deconvolves polygenic risk scores at the single-cell level to uncover cellular and molecular disease mechanisms in complex human diseases.

This paper presents a data-driven drug repositioning framework that identifies CVL218, a PARP1 inhibitor, as a potential therapeutic for COVID-19 through in silico and experimental validation.

MONN predicts non-covalent interactions and binding affinities between compounds and proteins, outperforming existing methods and providing interpretable insights.